The GLP-1 analogues prescribed for weight loss rely on a specific pharmacological mechanism: they mimic the action of the incretin hormone GLP-1, secreted by the L cells of the small intestine in response to food intake. Their prolonged half-life, achieved through structural modification of the native molecule, allows for weekly administration and stable pharmacological exposure.
Titration and dosing schedule: the parameter that prescribers underestimate
The dose escalation phase directly influences digestive tolerance and the long-term maintenance of treatment. Wegovy, for example, is available in five successive dosage levels, each maintained for four weeks before moving to the next. Skipping steps to reach the target dose exposes the patient to severe nausea and early discontinuation.
Related reading : Everything You Need to Know About Online Banks: Tips, Reviews, and Banking News
In practice, we observe that the titration of tirzepatide (Mounjaro) follows a similar logic but with different levels. The adjustment is not only based on gastrointestinal tolerance: the weight response at each level also guides the decision to continue escalating or to stabilize the dose.
The choice of injection site (abdomen, thigh, arm) and the systematic rotation of areas reduce the risk of local lipodystrophy. To better understand injections for weight loss, this technical dimension often absent from consumer guides must be integrated.
See also : Everything You Need to Know About Hytrack Quads: Features, Tips, and User Reviews
Reimbursement of Wegovy and Mounjaro in France: actual eligibility criteria
Since the decrees published in the Official Journal on May 28, 2026, Wegovy and Mounjaro are reimbursed at 65% by Health Insurance starting June 15, 2026. The remaining cost may be covered by supplementary health insurance. This advancement profoundly changes the accessibility of these treatments, but the scope of reimbursement remains much narrower than some media suggest.
The reimbursement does not cover simple overweight. The criteria focus on patients who would be eligible for bariatric surgery:
- BMI of 40 or higher without associated comorbidity, or BMI of 35 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, sleep apnea)
- Documented failure of prior nutritional management, defined as a weight loss of less than 5% in six months despite appropriate support
- Initial prescription reserved for specialized structures of level 2 or 3: specialized obesity centers (CSO), hospital services of CHU, or certain rehabilitation services
Outside this strict framework, these molecules can still be prescribed for patients with a BMI of 27 or higher (with comorbidity) or 30 or higher, but without any reimbursement. The monthly cost then remains entirely the patient’s responsibility.
Renewal and long-term follow-up
The renewal of the reimbursed prescription can be ensured by the primary care physician, but only after the initial hospital prescription. A semi-annual follow-up in a specialized structure is recommended by HAS to reassess the relevance of the treatment and monitor metabolic effects.
Semaglutide vs. Tirzepatide: concrete pharmacological differences
Wegovy (semaglutide) acts as a selective GLP-1 receptor agonist. Mounjaro (tirzepatide) simultaneously targets GLP-1 and GIP receptors, giving it a dual incretin mechanism. This distinction is not cosmetic: it translates into distinct efficacy and tolerance profiles.
In terms of weight reduction, available data suggest that tirzepatide produces a more pronounced weight loss than semaglutide at their respective maximum doses. The dual GLP-1/GIP agonism amplifies the glucose-dependent insulinotropic response and may modulate lipid metabolism differently.
Gastrointestinal side effects (nausea, vomiting, diarrhea) remain the main reason for discontinuation for both molecules. We recommend an individualized assessment: a type 2 diabetic patient with obesity may potentially benefit more from a dual agonist, while a patient without glycemic disorders may achieve satisfactory results with semaglutide alone.
Side effects of anti-obesity injections: beyond digestive disorders
Pharmacovigilance literature identifies signals that go beyond the classic gastrointestinal framework. The points of vigilance we note in consultation include:
- Risk of acute pancreatitis, low but documented, requiring immediate discontinuation of treatment in case of severe abdominal pain radiating to the back
- Change in body composition: weight loss includes a fraction of lean mass, necessitating support in resistance physical activity to limit sarcopenia
- Slowing of gastric emptying that may interfere with the absorption of other oral medications, a parameter to consider in poly-medicated patients
- Preclinical thyroid signals (C-cell tumors in rodents) justifying a formal contraindication in patients with a personal or family history of medullary thyroid carcinoma
Regular biological monitoring (liver function tests, renal function, lipase) is an integral part of the follow-up protocol. GLP-1 analogue treatment without structured medical follow-up exposes patients to disproportionate risks compared to the expected benefit.
Discontinuation of treatment and weight regain: the data that no one wants to hear
Discontinuing a GLP-1 analogue typically results in significant weight regain in the months that follow. This weight rebound reflects a return to the previous physiological state: the satiety induced by the molecule disappears, gastric emptying resumes its normal pace, and caloric intake increases.
This pharmacological reality raises the question of treatment duration. Current HAS recommendations position these injections as a second-line treatment, complementary to lifestyle modifications. They do not present them as a one-time cure. Nutritional management and physical activity remain the foundation without which the molecule produces only a temporary effect.